Description: Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Home Page: www.vir.bio
VIR Technical Analysis
499 Illinois Street
San Francisco,
CA
94158
United States
Phone:
415 906 4324
Officers
| Name | Title |
|---|---|
| Dr. George A. Scangos Ph.D. | Pres, CEO & Director |
| Mr. Howard Horn | Exec. VP, CFO & Sec. |
| Dr. Ann M. Hanly Ph.D. | Exec. VP & Chief Technology Officer |
| Dr. Phillip Pang M.D., Ph.D. | Exec. VP, Chief Medical Officer & Interim Head of Research |
| Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor |
| Ms. Johanna Friedl-Naderer | Exec. VP & COO |
| Mr. Steven J. Rice | Exec. VP & Chief Admin. Officer |
| Ms. Heather Rowe Armstrong | VP of Investor Relations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 4.3611 |
|---|---|
| Trailing PE: | 3.1311 |
| Price-to-Book MRQ: | 1.6037 |
| Price-to-Sales TTM: | 1.4094 |
| IPO Date: | 2019-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 444 |